Also in this context, the role of arylpierazine derivatives as serotonergic ligands emerges as having the potential to target serotonin and connective tissue growth factor (CTGF) signaling, while also ameliorating the sensitivity to Tamoxifen in ER+ breast cancer cells. The gene discussed is CCN2; the disease is breast carcinoma.